Copper-Curcumin-Bipyridine Dicarboxylate Complexes as Anticancer Candidates.

Area of Science:

• Inorganic Chemistry
• Materials Science
• Biochemistry

Background:

• Copper complexes are explored for their potential therapeutic applications.
• Curcumin and 2,2'-bipyridine-5,5'-dicarboxylic acid (BPYD) are ligands with known biological activities.
• Developing novel anticancer agents with improved efficacy and selectivity is a critical area of research.

Purpose of the Study:

• To synthesize and characterize novel copper complexes incorporating Curcumin (Cur) and 2,2'-bipyridine-5,5'-dicarboxylic acid (BPYD).
• To evaluate the in-vitro cytotoxicity of these synthesized copper complexes against the MDA-MB-231 human breast cancer cell line and the HUVEC normal cell line.
• To investigate the mechanism of action, specifically reactive oxygen species (ROS) production, in cancer cells treated with these complexes.

Main Methods:

• Synthesis of copper complexes with Curcumin and BPYD.
• Characterization using Fourier-transform infrared spectroscopy (FTIR), UV/Visible spectroscopy, CHNS elemental analysis, thermogravimetric analysis (TGA), inductively coupled plasma mass spectrometry (ICP-MS), and mass spectrometry.
• In-vitro cytotoxicity assays on MDA-MB-231 (cancer) and HUVEC (normal) cell lines, including determination of IC50 values.
• Measurement of reactive oxygen species (ROS) production using the 2',7'-dichlorofluorescein diacetate (DCFDA) assay.

Main Results:

• The synthesized copper complexes were successfully characterized by various spectroscopic and analytical techniques.
• All copper complexes demonstrated significantly higher cytotoxicity against MDA-MB-231 cancer cells compared to carboplatin (positive control).
• The Cu-Cur-BPYD complexes (a5 & b5) exhibited potent cytotoxicity with IC50 values of approximately 4.9 µM and 2.3 µM, respectively.
• The synthesized complexes showed minimal toxicity towards normal HUVEC cells, indicating selective anticancer activity.
• Increased ROS production was observed in MDA-MB-231 cells treated with the copper complexes.

Conclusions:

• The synthesized Cu-Cur-BPYD complexes possess significant in-vitro anticancer activity against the MDA-MB-231 cell line.
• These complexes display a favorable safety profile, being selectively toxic to cancer cells while sparing normal cells.
• The observed ROS generation suggests a potential mechanism contributing to their anticancer effects.
• The Cu-Cur-BPYD complexes (a5 & b5) represent promising candidates for further preclinical development as anticancer agents.